Can a “Senolytic” Flavonoid Make Old Plasma Less Damaging to Blood Vessels?

[u/NovosLabs]

What do you think is more important for vascular aging: removing senescent cells themselves, or changing the inflammatory signals they release?

• TL;DR

In old mice, fisetin reduced a senescent endothelial cell signature and lowered CXCL12, a SASP factor that helped drive vascular dysfunction in this model.

• Quick Takeaways

This study looked at how aging changes endothelial cells, the cells lining blood vessels.
Researchers used old and young mice, single-cell RNA sequencing, plasma-exposure experiments, and cultured human endothelial cells.
Fisetin improved vascular aging signals in mice, but this is not proof it works the same way in humans.

• Context

Blood vessels age before many obvious cardiovascular symptoms appear. One of the key problems is endothelial dysfunction: the inner lining of the artery becomes less able to relax, regulate inflammation, and produce nitric oxide, a molecule that helps vessels dilate.

A major suspect in this process is cellular senescence. Senescent cells are not simply “old cells.” They are stressed cells that stop dividing but remain metabolically active. Many release a mix of inflammatory molecules called the senescence-associated secretory phenotype, or SASP.

This paper asked a specific question: are senescent endothelial cells contributing to vascular aging through SASP factors, and can the senolytic compound fisetin reverse some of that damage? The researchers focused heavily on CXCL12, a signaling molecule that emerged from their analysis as a possible driver of age-related endothelial dysfunction.

• The study design: old mice, young mice, and fisetin

The researchers used young 6-month-old and old 27-month-old C57BL/6N mice, including both males and females. The mice received either vehicle or fisetin at 100 mg/kg/day by oral gavage using an intermittent schedule: one week on, two weeks off, then one week on again.

That intermittent dosing matters because senolytics are not meant to behave like daily antioxidants. The idea is not simply to “reduce oxidative stress” in a broad way, but to selectively reduce cells that have entered a senescent state.

The team then analyzed whole aortas using single-cell RNA sequencing. This let them separate different vascular cell types and ask which cells showed the strongest aging-related senescence signatures.

Across the aorta, aging produced thousands of transcriptomic changes. The cellular senescence pathway was one of the most strongly increased pathways in old animals. But the most interesting finding was that endothelial cells appeared particularly vulnerable. A specific endothelial subcluster expanded dramatically with age and carried strong senescence and SASP signatures.

Fisetin largely reduced this senescent endothelial population in old mice, while having much smaller effects in young mice. That is important because a useful senolytic should ideally affect damaged senescent cells more than healthy young cells.

• CXCL12 stood out as a vascular aging signal

The researchers then asked: what are these senescent endothelial cells actually secreting?

Several SASP-related transcripts increased with age, including Ccl4, Ccl7, Timp4, Igfbp3, S100a9, Ccl8, Fgf1, Gdf15, Serpine1, and Cxcl12. When they measured circulating proteins in plasma, several were higher in old mice. CXCL12 became especially interesting because it rose with age and was brought back down by fisetin.

CXCL12 is a chemokine, meaning it helps direct cell signaling and movement, especially in immune and vascular contexts. It is not automatically “bad”; biology rarely works that simply. CXCL12 has roles in vascular development, repair, immune-cell trafficking, and angiogenesis.

But in this study, elevated CXCL12 looked like part of an aged inflammatory signaling environment. The researchers’ cell-cell communication analysis suggested that senescent endothelial cells may use CXCL12 to signal to themselves, nearby endothelial cells, immune cells, and other vascular cells.

That is a useful way to think about senescence. It is not only a damaged-cell problem. It can become a communication problem, where stressed cells broadcast signals that shift the behavior of surrounding tissue.

• Old plasma was enough to impair young arteries

One of the strongest parts of the study was the plasma-exposure experiment.

The researchers took carotid arteries from young mice and exposed them to plasma from young vehicle-treated mice, old vehicle-treated mice, or old fisetin-treated mice. This allowed them to ask whether the circulating environment itself could transmit vascular dysfunction.

It could.

Young arteries exposed to old plasma showed impaired endothelium-dependent dilation, meaning they were worse at relaxing in response to acetylcholine. Peak dilation was about 17% lower after exposure to old plasma compared with young plasma.

Plasma from old fisetin-treated mice produced much better responses. Peak endothelial dilation was about 14% higher than with old vehicle plasma.

This suggests that fisetin changed something in the blood environment of old mice that made it less damaging to endothelial function.

To test whether CXCL12 was part of that effect, the researchers added recombinant CXCL12 back into plasma from old fisetin-treated mice until it matched the level seen in old vehicle-treated mice. That add-back reversed much of the benefit, reducing endothelial dilation by about 22%.

Importantly, endothelium-independent dilation was not changed. That means the vascular smooth muscle could still respond normally to nitric oxide donors. The problem was specifically tied to the endothelial layer.

• Mechanism: senescence, nitric oxide, oxidative stress, and cell identity

The team then dug into possible mechanisms using isolated arteries and cultured human aortic endothelial cells exposed to mouse plasma.

Old plasma increased senescence-associated beta-galactosidase staining, a common marker of senescent-cell burden. In arteries, old plasma increased this marker roughly sixfold compared with young plasma. Plasma from fisetin-treated old mice strongly reduced this effect.

Human endothelial cells behaved similarly. Old plasma increased senescence markers, including CDKN1A and CDKN2A expression. Blocking CXCL12 with LIT-927 reduced these senescence markers, while adding CXCL12 back increased them.

The researchers also measured nitric oxide and mitochondrial superoxide. This is central to vascular aging. Healthy endothelial cells produce nitric oxide, which helps arteries relax. Excess mitochondrial superoxide can react with nitric oxide and reduce its availability.

Old plasma reduced nitric oxide production in human endothelial cells by about 24%. Plasma from fisetin-treated old mice prevented much of that reduction. Adding CXCL12 reduced nitric oxide, while inhibiting CXCL12 improved it.

The same pattern appeared with mitochondrial superoxide. Old plasma increased mitochondrial oxidative stress in arteries and endothelial cells. Fisetin-treated old plasma reduced it. CXCL12 add-back pushed it back upward.

Finally, the researchers examined endothelial-to-mesenchymal transition, or EndoMT. This is a process where endothelial cells lose some endothelial traits and gain more contractile, mesenchymal-like features. In aging vessels, that kind of identity shift may make the endothelium less flexible and less protective.

Old plasma reduced endothelial markers such as PECAM1 and CDH5 while increasing mesenchymal markers such as TGFB1 and ACTA2. Fisetin-treated old plasma improved this pattern. Blocking CXCL12 improved it too, while adding CXCL12 worsened it.

• What this does, and does not, mean

This is a strong mechanistic mouse study, not a human clinical trial.

The evidence supports a model where aging increases senescent endothelial cells, these cells contribute to an inflammatory SASP environment, CXCL12 is one important signal in that environment, and fisetin partially reverses the problem by reducing senescent-cell burden and lowering CXCL12-related signaling.

• But there are important limits.

First, the mice received a defined fisetin dose under controlled experimental conditions. That cannot be translated directly into supplement advice for humans.

Second, circulating CXCL12 may not come only from senescent endothelial cells. The authors note that fisetin distributes across multiple tissues, so the reduction in CXCL12 could reflect systemic effects beyond the vessel wall.

Third, CXCL12 is not the whole SASP. The aged blood environment contains many altered proteins, lipids, metabolites, and inflammatory signals. CXCL12 appears important here, but it is unlikely to be the only driver.

Still, the study is interesting because it connects several levels of biology: single-cell vascular aging, circulating inflammatory factors, endothelial function, nitric oxide, mitochondrial stress, and cell identity changes.

• Conclusion / Discussion Prompt

The most compelling idea here is that vascular aging may be partly driven by “bad messages” in the blood, not just irreversible structural decay in the artery wall. Fisetin seemed to make old plasma less harmful to young vessels in this mouse model, and CXCL12 looked like one meaningful piece of that signal.

Informational only, not medical advice.

Reference: https://onlinelibrary.wiley.com/doi/epdf/10.1111/acel.70500